Dr Stahl speaks with ecancer at the ASH 2017 annual meeting about the use of hypomethylating agents for relapsed and refractory acute myeloid leukaemia the impact of the administration schedule and mutational profile on outcomes.
He describes how changes in dose scheduling and
Dr Stahl also spoke with ecancer about immune suppression for MDS patients, here.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.